TSX gains after CPI shows US inflation rose 3%
WALTHAM, Mass. - Revvity, Inc. (NYSE:RVTY) announced Thursday that its Board of Directors has declared a regular quarterly dividend of $0.07 per share of common stock. The dividend will be payable on February 6, 2026, to shareholders of record at the close of business on January 16, 2026. According to InvestingPro data, Revvity has maintained dividend payments for 55 consecutive years, demonstrating remarkable consistency in shareholder returns.
Revvity, a health science solutions provider, reported revenue of more than $2.7 billion in 2024, with a robust gross profit margin of 56% and a perfect Piotroski Score of 9, indicating strong financial health. The company employs approximately 11,000 people and serves customers in over 160 countries across pharmaceutical, biotech, diagnostic labs, academia, and government sectors.
The S&P 500 company specializes in providing technologies, expertise, and services that support complete healthcare workflows from discovery to development and diagnosis to cure, with focus areas including translational multi-omics technologies, biomarker identification, imaging, and diagnostics.
The dividend announcement was made in a press release issued by the company.
In other recent news, Revvity Inc. announced a collaboration with Sanofi to develop a population-scale assay for early detection of type 1 diabetes. This new initiative aims to expand Revvity’s offerings in the field and includes clinical validation and regulatory submissions. Additionally, Revvity launched its Living Image Synergy AI software, which is designed to enhance data analysis for in vivo imaging researchers by integrating multiple imaging modalities. On the financial front, KeyBanc reiterated its Overweight rating on Revvity, maintaining a price target of $125 despite lowering estimates based on management’s fiscal projections for 2025 and 2026. Stifel, on the other hand, reduced its price target for Revvity to $110 due to pressures in the China ImmunoDx segment, though they noted that second-quarter results met expectations. Guggenheim initiated coverage on Revvity with a Neutral rating, highlighting the company’s strong strategic and operational track record. These developments reflect various strategic and operational moves by Revvity in recent times.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.